ENG

Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer

PHILADELPHIA, June 25, 2007 /PRNewswire-USNewswire/ -- Childhoodcancers are fortunately rare, but among them, neuroblastoma is aspecial case, accounting for 7 percent of all childhood cancers,but 15 percent of childhood cancer deaths. It typically occurs as asolid tumor in the abdomen, but also in the neck, chest, andpelvis, developing in the network of the body's sympathetic nervoussyst...

Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine

SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, 2007- The Institute for OneWorld Health, a US-based non-profitpharmaceutical company, today announced that Phase 3 researchrelated to its first approved drug product, Paromomycin IMInjection (Paromomycin), was published in the current issue of TheNew England Journal of Medicine (NEJM). This clinical trial showsthat the medicine...

Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for Heart Failure

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 19, 2007 - GeronCorporation (Nasdaq: GERN) today reported that research documentingthe scalable production, survival following engraftment andpositive impact on cardiac function in infarcted rats was presentedtoday for GRNCM1, the company's human embryonic stem cell(hESC)-based therapeutic for heart failure, at the InternationalSociety for Stem Cell...

Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis

ECUBLENS, SWITZERLAND, June 07, 2007 /PRNewswire-FirstCall/ -Neurochem (International) Limited (Neurochem), a wholly-ownedsubsidiary of Neurochem Inc. , announces that the New EnglandJournal of Medicine (NEJM) published the results of the "EprodisateFor AA Amyloidosis Trial" (EFAAT), recognized as a landmarkclinical trial in the search for a treatment of AA amyloidosis. Theresults of the...

Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England

"The editorials published by the NEJM are disappointing andmisleading in that they disregarded important pieces of data thatare extremely relevant to patients and physicians. Mostsignificantly the editorials ignored data that showed no evidenceof any increase in cardiovascular death or death from anycause."...

8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar

Positive Results in Patients With Follicular Lymphoma ReportedToday at ASCO Annual Meeting PHILADELPHIA, June 04, 2007 /PRNewswire/ -- GlaxoSmithKline plcannounced today long-term efficacy data from a Phase II trial of asingle one-week course of frontline treatment with the BEXXAR(R)Therapeutic Regimen (Tositumomab and Iodine I-131 Tositumomab) in76 patients with newly diagnosed advanced...

New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma

- Positive data on subcutaneous administration show potential fornew option to improve convenience for patients - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today announced the presentation of positivedata for VELCADE, the market-leading therapy for patients withmultiple myeloma (MM) who have received at least one prior therapy.These data include resu...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

Abstracts: 2000, 2002 CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of aPhase I/IIa study presented today at the American Society ofClinical Oncology (ASCO) annual meeting in Chicago demonstrate theclinical activity of cilengitide in patients with newly diagnosedglioblastoma – a particularly aggressive form of brain tumor.Cilengitide i...

Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show

Study Presented at Second International Conference on AvianInfluenza at France's Pasteur Institute PARIS, June 01, 2007 /PRNewswire-FirstCall/ -- Very low doses ofNovavax Inc.'s pandemic influenza vaccine provided protectionagainst a lethal challenge of live H5N1 viruses, according topre-clinical data presented here today at the Second InternationalConference on Avian Influenza in Humans....

Annual Meeting of the Consortium of Multiple Sclerosis Centers Focuses on the Challenges of Care and Research in Multiple Sclerosis

WASHINGTON, June 01, 2007 /PRNewswire/ -- The annual meeting ofthe Consortium of Multiple Sclerosis Centers (CMSC), the largestmeeting devoted to the comprehensive care and science of multiplesclerosis (MS), is underway in the nation's capital today. Multiplesclerosis, a disease of the central nervous system that affects400,000 people in the United States, challenges patients, carepartne...

Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents

Risk of Late Thrombosis is Minimized with Genous Stent BARCELONA, Spain, May 23, 2007 /PRNewswire/ -- The efficacy ofOrbusNeich's Genous(TM) Bio-engineered R stent compares favorablyto that of drug-eluting stents, while the risk of late thrombosisis minimized with the Genous stent, according to an interimanalysis of post-marketing data presented today by Robbert deWinter, M.D., Ph.D., at...

SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems

SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACEafter one year NATICK, Mass. and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todaywelcomed the results of additional data from the SPIRIT FIRST, IIand III Clinical Trials, reaffirming prior safety and efficacy datafor the market-leading TAXUS(R) Express2(TM) Paclitaxel-ElutingCorona...

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--May21, 2007 - ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) notesthe publication of new clinical data relevant to the developmentstrategy for Ceflatonin(R) (homoharringtonine). The paper "Targetedtherapy and the T315I mutation in Philadelphia-positive leukemias"by researchers Simona Soverini and colleagues at the University...

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia, and MENLO PARK, CaliforniaU.S.A. (May 21, 2007): ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ:CXSP) notes the publication of new clinical data relevant to thedevelopment strategy for Ceflatonin® (homoharringtonine). Thepaper "Targeted therapy and the T315I mutation inPhiladelphia-positive leukemias" by researchers Simona Soverini andcolleagues at...

New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace

First comprehensive study of market dynamics offers insights intowhat will be needed to get new, faster and better TB drugs topatients NEW YORK, May 14, 2007 /PRNewswire-USNewsire/ -- The GlobalAlliance for TB Drug Development (TB Alliance), a not-for-profit,product development partnership accelerating the discovery anddevelopment of new TB drugs, today released results from the firstcom...

Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in Preclinical Studies

LUCCA, Italy--(BUSINESS WIRE)--May 14, 2007 - Acceleron Pharma,Inc., a biopharmaceutical company developing therapeutics for thetreatment of musculoskeletal, metabolic and cancer-relateddiseases, today announced results of a preclinical study withACE-031 that demonstrated the ability of the compound to increasemuscle mass and strength in normal mice and in murine models ofmuscular dystrophy...

New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-May 10, 2007--Today, theNew England Journal of Medicine is publishing results from twoPhase III studies of Merck's cervical cancer vaccine, Gardasil(Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18)Recombinant Vaccine). In the first study, Gardasil provided 100percent protection against cervical, vaginal and vulvar diseasescaused by the four H...

Novavax Reports Positive Pre-Clinical Study Results from Live Virus Challenge to Pandemic Flu Vaccine

Ferret Study to be Part of Data Package Required to Begin ClinicalTrials ROCKVILLE, Md., May 03, 2007 /PRNewswire-FirstCall/ -- NovavaxInc. said today that it has received positive study results from alive virus challenge to ferrets inoculated with its pandemicinfluenza vaccine, paving the way for clinical trials to begin onschedule later this year. In the study, ferrets were inocu...

LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic Protection Against Influenza Challenge With Virus-Like Particle Immunization

BOZEMAN, Mont., May 01, 2007 /PRNewswire/ -- LigoCytePharmaceuticals presented preclinical data today showing thatimmunization with their influenza virus-like particles (VLPs)induced heterosubtypic protection in a virus challenge study. Thecompany's data were presented by Dr. Joel Haynes, LigoCyte's seniordirector of vaccine development, at the Tenth Annual Conference onVaccine Research...

Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C

Highlights key data at the 42nd annual meeting of the EuropeanAssociation for the Study of the Liver (EASL) KENILWORTH, N.J., April 11, 2007 /PRNewswire-FirstCall/ --Schering-Plough Corporation reaffirms its commitment to advancingthe science and treatment of chronic hepatitis C virus (HCV)infection with several key data presentations at the EuropeanAssociation for the Study of the Liver...